RNAZ · Categories · M&A
RNAZ - Mergers and acquisitions
TransCode Therapeutics Inc. (RNAZ) mergers and acquisitions - real-time wire coverage filtered to M&A only.
Recent M&A for RNAZ
- TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology companyTransCode acquires 100% of the issued and outstanding interests of Polynoma from CK Life SciencesConcurrent equity investment of $25 Million from CK Life Sciences into TransCodeTransCode expands its microRNA-based pipeline with Polynoma's Phase 3-ready seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant treatment of melanomaPhilippe Calais, PharmD, PhD, becomes Chief Executive Officer and remains Chairman of the Board. Tom Fitzgerald, MBA, remains Chief Financial Officer. Elizabeth Czerepak, MBA, appointed as a new independent Board Member and Chairperson of the Audit CommitteeBOSTON and SAN DIEGO, Oct. 8, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ) (
- TransCode Therapeutics Acquires Option for Radiotheranostic TechnologyBOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, is pleased to announce its execution of an option agreement giving TransCode the right to negotiate an exclusive, worldwide, royalty-bearing license related to a radiotheranostic technology disclosed in patent application PCT/US2021/057912 entitled THERAPEUTIC, RADIOLABLED NANOPARTICLES AND METHODS OF USE THEREOF. Invented by TransCode Co-Founder and CTO, Dr. Zdravka Medarova, and her colleagues at Massachusetts General Hospital, the technology represents another potential advancement in the diagnosis and treatment of cancer.